Cargando…

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy

Detalles Bibliográficos
Autores principales:	Liang, Zuyu, Cui, Jiazhen, Chang, Alex Hongsheng, Yu, Jian, Hu, Yongxian, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japanese Society for Regenerative Medicine 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770422/ https://www.ncbi.nlm.nih.gov/pubmed/33426230 http://dx.doi.org/10.1016/j.reth.2020.11.001

Ejemplares similares

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

S113: IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Cai, Zihong, et al.
Publicado: (2023)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
por: Thielen, Frederick W., et al.
Publicado: (2020)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation
por: Xu, Qianwen, et al.
Publicado: (2022)

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
por: Dai, Zhenyu, et al.
Publicado: (2022)

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
por: Zhou, Hui, et al.
Publicado: (2018)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
por: Elsallab, Magdi, et al.
Publicado: (2023)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Roddie, Claire, et al.
Publicado: (2021)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
por: Nguyen, Thi Thuy, et al.
Publicado: (2023)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells
por: Mikhailova, Ekaterina, et al.
Publicado: (2021)

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia
por: Ruiz-Ciancio, Dario, et al.
Publicado: (2023)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
por: Meckler, Joshua F., et al.
Publicado: (2023)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dkd3mec1usqcn7i748m6ii759g